11. Bibliografia

  1. Memduh U, et al. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22:441-457.
  2. Miserez AR, et al. Prediction of the therapeutic response to simvastatin by pretreatment lipid concentration in 2082 subjects. Eur J Clin Pharmacol 1994; 46:107-114.
  3. Davidson MH, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997; 79:38-42.
  4. Kantola T, et al. PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol 1998; 64:177-182.
  5. Pichard L, et al. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. Biochem Pharmacol 1996; 51:591-598.
  6. Arnadottir M, et al. Plasma concentration profiles of simvastatin 3-hydroxy-3-metylglutaryl-Co-enzyme A reductase inhibitory activity in kidney tranplant recipiens with and without cyclosporin. Nephron 1993; 65:410-413.
  7. Kantola T, et al. Effect of itraconazole or the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64:58-65.
  8. Segaert MF, et al. Drug-interaction-induced rhabdomyolisis. Nephrol Dial Transplant 1996; 11:1846-7.
  9. Wu CY, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 58:492-497.
  10. Kogan AD, Orensterin S. Lovastatin-induced acute rhabdomyolysis. Postgrad Med J 1990; 66: 293-296.
  11. Pierce LR, et al. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-75.
  12. Duell PB, et al. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998; 81: 368-369.
  13. Van Puijenbroek EP, et al. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 1996; 240: 403-404.
  14. Tal A, et al. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J 1997; 90: 546-547.
  15. Goldman JA, et al. The role of cholesterol-lowering agents in drug induced rhabdomyolysis and polymyositis. Arthritis Rheum 1989; 32: 358-359.
  16. Panucio V, et al. Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient. Nephron 1996; 73: 736.
  17. Lane RJM, Mastaglia FL. Drug induced myopathies in man. Lancet 1978; II (8089): 562-566.
  18. Imai Y, et al. Muscle cramps and elevated serum creatine phosphokinase levels induced by beta-adrenoreceptor blockers. Eur J Clin Pharmacol 1995; 48: 29-34.
  19. Korzets A, et al. Severe hyponatremia after water intoxication: a potential cause of rhabdomyolysis. Am J Med Sci 1996; 12: 92-4.
  20. Melberg A, et al. Rhabdomyolysis in autosomal dominant progressive external ophtalmoplegia. Neurology 1998; 50: 299-300.
  21. Engel WK, et al. A skeletal-muscle disorder associated with intermittent symptoms and possible defect of lipid metabolism. N Engl J Med 1970; 282: 697-704.
  22. Carrascosa M, et al. Rhabdomyolysis associated with acute Q fever. Clin Infect Dis 1997; 25: 1243-1244.
  23. Prendergast BD, George CF. Drug-induced rhabdomyolysis -- mechanisms and management. Postgrad Med J 1993; 69: 333-336.
Precedente
Indice